Login to Your Account

Pharma: Clinic Roundup

Friday, November 8, 2013
• Boehringer Ingelheim GmbH, of Ingelheim, Germany, and Eli Lilly and Co., of Indianapolis, reported data from a pooled analysis of 17 trials testing linagliptin in people with Type II diabetes and self-reported previous/current liver and biliary disease, with results showing linagliptin demonstrated a statistically significant placebo-adjusted reduction in HbA1c of 0.52 and 0.62 percent in patients with and without hepatobiliary disorders, respectively, from baseline to 24 weeks.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription